MedTrace Logo

Pharmacokinetics in Extracorporeal Membrane Oxygenation

NCT03766282 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2018-12-06

No results posted yet for this study

Summary

The main purpose of the present study is to investigate the risk factors that affect drug pharmacokinetic (PK) during extracorporeal membrane oxygenation (ECMO). To advance understanding of PK variance and improve the patients outcomes during ECMO.

Conditions

  • Extracorporeal Membrane Oxygenation
  • Pharmacokinetics

Interventions

DEVICE

ECMO

Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure

Sponsors & Collaborators

  • China-Japan Friendship Hospital

    lead OTHER

Principal Investigators

  • Chen Wang · China-Japan Friendship Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2020-07-01
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03766282 on ClinicalTrials.gov